ArticleAsian Pacific journal of cancer prevention : APJCP2025
Salivary Expression of Cyclophilin A and FK506-Binding Protein 51 in Oral Submucous Fibrosis Versus Healthy Controls: A Cross-Sectional Analysis.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FKBP10 may affect the malignant phenotype of oral squamous cell carcinoma cells through the ECM/WNT signaling pathway.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunophilins, a group of proteins comprising FK506-binding proteins (FKBPs) and cyclophilins (Cyps), have been increasingly recognized as key contributors to fibrosis development in multiple organs, including the lungs, liver, heart, and bone marrow. The identification of immunophilins as potential therapeutic targets opens avenues for the development of inhibitory agents designed to impede both the initiation and progression of fibrosis. AIM AND
objectiveThis research aims to assess the levels of two vital salivary immunophilins- Cyclophilin A (CyP A) and FK506-binding protein 51 (FKBP 51), in OSMF patients. The central goal is to quantify and then juxtapose the salivary concentration of CyP A and FKBP 51 in this specific patient group and healthy controls. MATERIAL AND METHODOLOGY: Saliva was collected from 32 subjects in the study group and 32 subjects in the healthy control group using an unstimulated spitting method. Salivary CyP A and FKBP51 levels were measured using sensitive and precise enzyme-linked immunosorbent assay (ELISA) kits. Statistical analysis was performed using the independent samples t-test to determine statistical significance.
resultsThe study demonstrated a statistically significant elevation in CyP A levels among subjects with OSMF (mean ± SD: 45.414 ± 9.69 ng/mL) compared to healthy controls (mean ± SD: 8.243 ± 4.32 ng/mL; p < 0.001). It also showed a statistically significant increase in FKBP 51 levels in patients with oral submucous fibrosis (mean ± SD: 23.857 ± 5.45 ng/mL) compared to healthy individuals (mean ± SD: 5.829 ± 2.82 ng/mL; p < 0.001).
conclusionThis study substantiates that the elevated salivary concentrations of CyP A and FKBP 51 in OSMF patients suggest their potential utility as a markers for diagnosis and prognosis of the same, offering the potential for timely intervention, more effective treatment planning, and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.